<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718025</url>
  </required_header>
  <id_info>
    <org_study_id>2019/ABM/01/00009</org_study_id>
    <nct_id>NCT04718025</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome</brief_title>
  <acronym>ELECTRA-SIRIO</acronym>
  <official_title>Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome: the Randomized, Multicenter, Double-blind ELECTRA RCT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Agency (Poland)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ELECTRA-SIRIO 2 study is a randomized, multicenter, double-blind, investigator-initiated&#xD;
      clinical trial aimed to evaluate safety and efficacy of two ticagrelor-based de-escalation&#xD;
      antiplatelet strategies in patients with acute coronary syndrome (ACS). During the&#xD;
      hospitalization due to ACS, participants will be randomized in a 1:1:1 ratio into one of&#xD;
      three arms: low-dose ticagrelor with aspirin (LDTA), low-dose ticagrelor with placebo (LDTP),&#xD;
      and standard-dose ticagrelor with aspirin (SDTA), the latter being the control arm. Up to day&#xD;
      30, all enrolled patients will receive standard-dose ticagrelor (2x90mg) + aspirin (1x100mg).&#xD;
      Starting from day 31 LDTA and LDTP patients will receive low-dose ticagrelor (2x60mg) +&#xD;
      aspirin (1x100mg), SDTA - continuation of previous treatment. Starting from day 91 LDTP&#xD;
      patients will receive low-dose ticagrelor (2x60mg) + placebo, SDTA and LDTA - continuation of&#xD;
      previous treatment. The aim of the study is to evaluate the influence of ticagrelor&#xD;
      maintenance dose reduction from 2x90mg to 2x60mg with or without continuation of aspirin&#xD;
      versus dual antiplatelet therapy with standard dose ticagrelor in reducing clinically&#xD;
      relevant bleeding and maintaining anti-ischemic efficacy in ACS patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BARC type 2, 3 or 5 bleeding</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>The primary safety composite end point of this study is the first occurrence of type 2, 3 or 5 bleeding according to the BARC criteria, occurring during the first 12 months after ACS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death from any cause, nonfatal MI or nonfatal stroke.</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>The primary efficacy end point is the composite of death from any cause, first nonfatal MI, or first nonfatal stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from any cause, nonfatal MI, nonfatal stroke, BARC type 2, 3, or 5 bleeding.</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>The key secondary endpoint, net clinical effect, was defined as composite of death from any cause, nonfatal MI, or nonfatal stroke, and the first occurrence of BARC type 2, 3, or 5 bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC type 3 or 5 bleeding</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>Composite of the first occurrence of type 3 or 5 bleeding according to the BARC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI major or minor bleeding</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>Composite of the first occurrence of major or minor bleeding according to the TIMI criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GUSTO moderate, severe, or life-threatening bleeding</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>Composite of the first occurrence of moderate, severe, or life-threatening bleeding according to the GUSTO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISTH major bleeding</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>The first occurrence of major bleeding according to the ISTH criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>Death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from cardiovascular causes</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>Death from cardiovascular causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>Occurrence of myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>Occurrence of ischemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite or probable stent thrombosis</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>Occurrence of definite or probable stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>12 months after ACS</time_frame>
    <description>Occurrence of dyspnea</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>STEMI</condition>
  <condition>NSTEMI</condition>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>Low-dose ticagrelor with aspirin (LDTA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, and will receive the following antiplatelet therapy:&#xD;
ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;&#xD;
ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until 12 months after ACS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose ticagrelor with placebo (LDTP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, followed by discontinuation of aspirin after 3 months post-ACS, and will receive the following antiplatelet therapy:&#xD;
ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;&#xD;
ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until day 90 after ACS;&#xD;
ticagrelor 2x60mg + placebo starting from day 91 until 12 months after ACS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-dose ticagrelor with aspirin (SDTA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with ACS in this arm will receive standard dual antiplatelet therapy including ticagrelor 2x90mg + aspirin 1x100mg during the whole 12 months after ACS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg</intervention_name>
    <description>Up to day 30 after ACS, all enrolled patients will receive standard-dose ticagrelor 2x90mg as a part of dual antiplatelet therapy. Participants in SDTA arm will continue treatment with ticagrelor 2x90mg until 12 months post-ACS, while patients in LDTA and LDTP will be switched to low-dose ticagrelor 2x60 mg starting on day 31.</description>
    <arm_group_label>Standard-dose ticagrelor with aspirin (SDTA)</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 60mg</intervention_name>
    <description>Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.</description>
    <arm_group_label>Low-dose ticagrelor with aspirin (LDTA)</arm_group_label>
    <arm_group_label>Low-dose ticagrelor with placebo (LDTP)</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.</description>
    <arm_group_label>Low-dose ticagrelor with aspirin (LDTA)</arm_group_label>
    <arm_group_label>Standard-dose ticagrelor with aspirin (SDTA)</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of STEMI or NSTEMI or unstable angina&#xD;
&#xD;
          -  for patients with STEMI, the following three inclusion criteria will have to be met:&#xD;
             1) new ST-elevation at the J-point in two contiguous leads with the cut-point ≥1 mm in&#xD;
             all leads other than leads V2-V3, where the following cut-points apply: ≥2mm in men&#xD;
             ≥40 years; ≥2.5 mm in men &lt;40 years, or ≥1.5 mm in women regardless of age; or a new&#xD;
             left bundle-branch block 2) the intention to perform primary PCI 3) detection of a&#xD;
             rise and/or fall of cardiac troponin values with at least one value above the 99th&#xD;
             percentile upper reference limit&#xD;
&#xD;
          -  for patients with NSTEMI or unstable angina, at least two of the following three&#xD;
             criteria will have to be met:&#xD;
&#xD;
               1. symptoms indicating myocardial ischaemia&#xD;
&#xD;
               2. ST-segment changes on electrocardiography indicating myocardial ischaemia&#xD;
&#xD;
               3. detection of a rise and/or fall of cardiac troponin values with at least one&#xD;
                  value above the 99th percentile upper reference limit in addition to at least one&#xD;
                  of the following:&#xD;
&#xD;
               1. ≥60 years of age;&#xD;
&#xD;
               2. previous MI or coronary artery by-pass grafting;&#xD;
&#xD;
               3. ≥50% stenosis in ≥2 coronary arteries;&#xD;
&#xD;
               4. previous ischaemic stroke or transient ischaemic attack;&#xD;
&#xD;
               5. ≥50% carotid stenosis or cerebral revascularisation;&#xD;
&#xD;
               6. diabetes mellitus;&#xD;
&#xD;
               7. peripheral artery disease;&#xD;
&#xD;
               8. chronic kidney disease with glomerular filtration rate &lt;60 mL/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindications to ticagrelor or/and aspirin&#xD;
&#xD;
          -  indications for oral anticoagulation therapy&#xD;
&#xD;
          -  second or third grade atrio-ventricular block&#xD;
&#xD;
          -  previous stent thrombosis on treatment with ticagrelor&#xD;
&#xD;
          -  end stage kidney disease with glomerular filtration rate &lt;15 mL/min or on&#xD;
             haemodialysis&#xD;
&#xD;
          -  administration of prasugrel during the index event&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Kubica, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piotr Adamski, MD, PhD</last_name>
    <phone>+48 52 585 4023</phone>
    <email>piotr.adamski@cm.umk.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antoni Jurasz University Hospital No. 1</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Piotr Adamski, MD, PhD</last_name>
      <phone>+48 585 4023</phone>
      <email>piotr.adamski@cm.umk.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collegium Medicum w Bydgoszczy</investigator_affiliation>
    <investigator_full_name>Jacek Kubica</investigator_full_name>
    <investigator_title>Prof. dr hab.</investigator_title>
  </responsible_party>
  <keyword>ticagrelor</keyword>
  <keyword>aspirin</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

